

Selected publications

2022

1. Ugalde-Morales E, Grassmann F, Humphreys K, Li J, Eriksson M, Tobin NP, Lindstrom LS, Vallon-Christersson J, Borg A, Hall P, **Czene K**. Interval breast cancer is associated with interferon immune response. *European Journal of Cancer*. 2022;162:194-205. doi: 10.1016/j.ejca.2021.12.003.

2021

2. Azam S, Eriksson M, Sjolander A, Gabrielson M, Hellgren R, **Czene K**, Hall P. Mammographic microcalcifications and risk of breast cancer. *British Journal of Cancer*. 2021;125(5):759-65. doi: 10.1038/s41416-021-01459-x.
3. Eriksson M, **Czene K**, Hall P. Identification of women at high risk of breast cancer and in need of supplemental screening - A cohort study. *Cancer Research*. 2021;81(4).
4. Grassmann F, Yang H, Eriksson M, Azam S, Hall P, **Czene K**. Mammographic features are associated with cardiometabolic disease risk and mortality. *European Heart Journal*. 2021. doi: 10.1093/eurheartj/ehab502.
5. He W, Eriksson M, Eliasson E, Grassmann F, Backlund M, Gabrielson M, Hammarstrom M, Margolin S, Thoren L, Wengstrom Y, Borgquist S, Hall P, **Czene K**. CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial. *Annals of Oncology*. 2021. doi: 10.1016/j.annonc.2021.07.005.
6. Johansson A, Christakou AE, Iftimi A, Eriksson M, Tapia J, Skoog L, Benz CC, Rodriguez-Wallberg KA, Hall P, **Czene K** and Lindstrom LS. Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden. *JAMA Network Open*. 2021;4(6):e2114716.
7. Isheden G, Grassmann F, **Czene K** and Humphreys K. Lymph node metastases in breast cancer: Investigating associations with tumor characteristics, molecular subtypes and polygenic risk score using a continuous growth model. *International Journal of Cancer*. 2021.
8. Eriksson M, Eklund M, Borgquist S, Hellgren R, Margolin S, Thoren L, Rosendahl A, Lang K, Tapia J, Backlund M, Discacciati A, Crippa A, Gabrielson M, Hammarstrom M, Wengstrom Y, **Czene K** and Hall P. Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial. *Journal of Clinical Oncology*. 2021;39(17):1899-908.
9. Azam S, Eriksson M, Sjolander A, Gabrielson M, Hellgren R, **Czene K** and Hall P. Predictors of mammographic microcalcifications. *International Journal of Cancer*. 2021;148(5):1132-43.
10. Eriksson M, **Czene K**, Conant EF and Hall P. Use of Low-Dose Tamoxifen to Increase Mammographic Screening Sensitivity in Premenopausal Women. *Cancers (Basel)*. 2021;13(2). doi: 10.3390/cancers13020302.
11. Holm J, Yu NY, Johansson A, Ploner A, Hall P, Lindstrom LS and **Czene K**. Concordance of Immunohistochemistry-Based and Gene Expression-Based Subtyping in Breast Cancer. *JNCI Cancer Spectrum*. 2021;5(1). doi: 10.1093/jncics/pkaa087
12. Hu K, Eriksson M, Wengstrom Y, **Czene K**, Hall P and Fang F. Sense of coherence and risk of breast cancer. *Elife*. 2020;9.
13. Tan PS, Ali MA, Eriksson M, Hall P, Humphreys K and **Czene K**. Mammography features for early markers of aggressive breast cancer subtypes and tumor characteristics: A population-based cohort study. *International Journal of Cancer*. 2021;148(6):1351-9.

14. Ugalde-Morales E, Grassmann F, Humphreys K, Li J, Eriksson M, Tobin NP, Borg A, Vallon-Christersson J, Hall P and **Czene K**. Association between breast cancer risk and disease aggressiveness: Characterizing underlying gene expression patterns. *International Journal of Cancer*. 2021;148(4):884-94.
15. Hagg S, Jylhava J, Wang Y, **Czene K** and Grassmann F. Deciphering the genetic and epidemiological landscape of mitochondrial DNA abundance. *Human Genetics*. 2020. 2021;140(6):849-61.

2020

16. He W, Felix Grassmann F, Eriksson M, Eliasson E, Margolin, Thorén SL, Hall P, **Czene K**. CYP2D6 genotype predicts tamoxifen discontinuation and prognosis in breast cancer patients. *Journal of Clinical Oncology*. 2020 Feb 20;38(6):548-557.
17. Eriksson M, **Czene K**, Strand F, Zackrisson S, Lindholm P, Lang K, Fornvik D, Sartor H, Mavaddat N, Easton D and Hall P. Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening. *Radiology*. 2020;297(2):327-33.
18. Grassmann F, Pawitan Y and **Czene K**. A systems genomics approach to uncover the molecular properties of cancer genes. *Scientific Report*. 2020;10(1):18392.
19. Azam S, Eriksson M, Sjolander A, Hellgren R, Gabrielson M, **Czene K** and Hall P. Mammographic Density Change and Risk of Breast Cancer. *Journal of the National Cancer Institute*. 2020;112(4):391-9.
20. Gabrielson M, Azam S, Hardell E, Holm M, Ubhayasekera KA, Eriksson M, Backlund, M, Bergquist, J, **Czene, K** and Hall, P. Hormonal determinants of mammographic density and density change. *Breast Cancer Research*. 2020;22(1):95.
21. Holowko N, Eriksson M, Kuja-Halkola R, Azam S, He W, Hall P and **Czene K**. Heritability of Mammographic Breast Density, Density Change, Microcalcifications, and Masses. *Cancer Research*. 2020;80(7):1590-600.
22. Lu D, Song J, Lu Y, Fall K, Chen X, Fang F, Landen M, Hultman CM, **Czene K**, Sullivan P, Tamimi RM and Valdimarsdottir UA. A shared genetic contribution to breast cancer and schizophrenia. *Nature Communications*. 2020;11(1):4637.
23. Rainey L, Eriksson M, Trinh T, **Czene K**, Broeders MJM, van der Waal D and Hall P. The impact of alcohol consumption and physical activity on breast cancer: The role of breast cancer risk. *International Journal of Cancer*. 2020;147(4):931-9.
24. Yang H, Holowko N, Grassmann F, Eriksson M, Hall P and **Czene K**. Hyperthyroidism is associated with breast cancer risk and mammographic and genetic risk predictors. *BMC Medicine*. 2020;18(1):225.

2019

25. Grassmann F, He W, Eriksson M, Gabrielson M, Hall P and **Czene K**. Other cancers are associated with breast cancer mode of detection: novel insights into interval cancer genetics. *Nature Communications*, 2019 Oct 22;10(1):4648.
26. He W, Eriksson L, Tornberg S, Strand F, Hall P and **Czene K**. Discontinuation of adjuvant hormone therapy among breast cancer patients not previously attending mammography screening. *BMC Medicine*. 2019;17(1):24.
27. Li J, Wen WX, Eklund M, Kvist A, Eriksson M, Christensen HN, Torstensson A, Bajalica-Lagercrantz S, Dunning AM, Decker B, Allen J, Luccarini C, Pooley K, Simard J, Dorling L, Easton DF, Teo SH, Hall P, Borg A, Gronberg H and **Czene K**. Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. *International Journal of Cancer*. 2019;144(5):1195-204.

28. Strand F, Azavedo E, Hellgren R, Humphreys K, Eriksson M, Shepherd J, Hall P and **Czene K**. Localized mammographic density is associated with interval cancer and large breast cancer: a nested case-control study. *Breast Cancer Research*. 2019;21(1):8.
29. Yang H, Pawitan Y, He W, Eriksson L, Holowko N, Hall P, **Czene K**. Disease trajectories and mortality among women diagnosed with breast cancer. *Breast Cancer Research*. 2019;21(1):95.
30. Yu NY, Iftimi A, Yau C, Tobin NP, van 't Veer L, Hoadley KA, Benz CC, Nordenskjold B, Fornander T, Stal O, **Czene K**, Esserman LJ, Lindstrom LS. Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer. *JAMA Oncology*. 2019.
31. Azam S, Eriksson M, Sjolander A, Hellgren R, Gabrielson M, **Czene K**, Hall P. Mammographic Density Change and Risk of Breast Cancer. *Journal of National Cancer Institute*. 2019.
32. Skytthe A, Harris JR, **Czene K**, Mucci L, Adami HO, Christensen K, Hjelmborg J, Holm NV, Nilsen TS, Kaprio J, Pukkala E. Cancer Incidence and Mortality in 260,000 Nordic Twins With 30,000 Prospective Cancers. *Twin Research and Human Genetics*. 2019;22(2):99-107.
33. Isheden G, Abrahamsson L, Andersson T, **Czene K**, Humphreys K. Joint models of tumour size and lymph node spread for incident breast cancer cases in the presence of screening. *Statistical Methods in Medical Research*. 2019;28(12):3822-42.
34. Ooi BNS, Loh H, Ho PJ, Milne RL, Giles G, Gao C, Kraft P, John EM, Swerdlow A, Brenner H, Wu AH, Haiman C, Evans DG, Zheng W, Fasching PA, Castelao JE, Kwong A, Shen X, **Czene K**, Hall P, Dunning A, Easton D, Hartman M, Li J. The genetic interplay between body mass index, breast size and breast cancer risk: a Mendelian randomization analysis. *International Journal of Epidemiology*. 2019;48(3):781-94.

2018

35. Li J, Ugalde-Morales E, Wen WX, Decker B, Eriksson M, Torstensson A, Christensen HN, Dunning AM, Allen J, Luccarini C, Pooley KA, Simard J, Dorling L, Easton DF, Teo SH, Hall P and **Czene K**. Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer. *Cancer Research*. 2018;78(21):6329-38.
36. Li J, Humphreys K, Ho PJ, Eriksson M, Darai-Ramqvist E, Lindstrom LS, Hall P, **Czene K**. Family History, Reproductive, and Lifestyle Risk Factors for Fibroadenoma and Breast Cancer. *JNCI Cancer Spectrum*. 2018;2(3):pky051.
37. Eriksson L, He W, Eriksson M, Humphreys K, Bergh J, Hall P and **Czene K**. Adjuvant therapy and mammographic density changes in women with breast cancer. *JNCI Cancer Spectrum*, Volume 2, Issue 4, October 2018, pky071.
38. Brand JS, Humphreys K, Li J, Karlsson R, Hall P and **Czene K**. Common genetic variation and novel loci associated with volumetric mammographic density. *Breast Cancer Research* 2018;20(1):30.
39. Eriksson L, Bergh J, Humphreys K, Warnberg F, Tornberg S and **Czene K**. Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: A population-based cohort study. *International Journal of Cancer* 2018.
40. Yang H, He W, Eriksson M, Li J, Holowko N, Chiesa F, Hall P and **Czene K**. Inherited factors contribute to an inverse association between preeclampsia and breast cancer. *Breast Cancer Research*. 2018;20(1):6.
41. Strand F, Humphreys K, Holm J, Eriksson M, Tornberg S, Hall P, Azavedo E, Czene K. Long-term prognostic implications of risk factors associated with tumor size: a case study of women regularly attending screening. *Breast Cancer Research*. 2018;20(1):31.
42. (more than 50 authors) Wu L, Shi W, Long J, Guo X, Michailidou K, ..., **Czene K**, ..., and Zheng W. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. *Nature Genetics*. 2018;50(7):968-78.

43. Lindstrom LS, Yau C, **Czene K**, Thompson CK, Hoadley KA, Van't Veer LJ, Balassanian R, Bishop JW, Carpenter PM, Chen YY, Datnow B, Hasteh F, Krings G, Lin F, Zhang Y, Nordenskjold B, Stal O, Benz CC, Fornander T, Borowsky AD, Esserman LJ, Group STOT. Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer. *Journal of National Cancer Institute*. 2018;110(7):726-33.
44. Bystrom S, Eklund M, Hong MG, Fredolini C, Eriksson M, **Czene K**, Hall P, Schwenk JM, Gabrielson M. Affinity proteomic profiling of plasma for proteins associated to area-based mammographic breast density. *Breast Cancer Research*. 2018;20(1):14.

2017

45. Brand JS, Hedayati E, Bhoo-Pathy N, Bergh J, Hall P, Humphreys K, Ludvigsson JF and **Czene K**. Time-dependent risk and predictors of venous thromboembolism in breast cancer patients: A population-based cohort study. *Cancer*. 2017;123(3):468-475.
46. Holm J, Eriksson L, Ploner A, Eriksson M, Rantalainen M, Li J, Hall P and **Czene K**. Assessment of Breast Cancer Risk Factors Reveals Subtype Heterogeneity. *Cancer Research*. 2017;77(13):3708-17.
47. Li J, Ivansson E, Klevebring D, Tobin NP, Lindstrom LS, Holm J, Prochazka G, Cristando C, Palmgren J, Tornberg S, Humphreys K, Hartman J, Frisell J, Rantalainen M, Lindberg J, Hall P, Bergh J, Gronberg H and **Czene K**. Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes. *Clinical Cancer Research*. 2017;23(10):2584-92.
48. He W, Lindstrom LS, Hall P and **Czene K**. Cause-specific mortality in women with breast cancer in situ. *International Journal of Cancer*. 2017;140(11):2414-21.
49. He W, Smedby KE, Fang F, Olsson H, Margolin S, Hall P, **Czene K**. Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients. *Journal of National Cancer Institute*. 2017;109(10).
50. He W, Sofie Lindstrom L, Hall P, **Czene K**. Cause-specific mortality in women with breast cancer in situ. *International Journal of Cancer*. 2017;140(11):2414-21.
51. Lee M, Reilly M, Lindstrom LS and **Czene K**. Differences in survival for patients with familial and sporadic cancer. *International Journal of Cancer*. 2017;140(3):581-90.
52. Li J, Eriksson M, He W, Hall P and **Czene K**. Associations between childhood body size and seventeen adverse outcomes: analysis of 65,057 European women. *Scientific Reports*. 2017;7(1):16917.
53. Renkonen S, Lee M, Makitie A, Lindstrom LS and **Czene K**. Site-specific familial risk and survival of familial and sporadic head and neck cancer. *International Journal of Cancer*. 2017;141(3):497-502.
54. Strand F, Humphreys K, Eriksson M, Li J, Andersson TM, Tornberg S, Azavedo E, Shepherd J, Hall P and **Czene K**. Longitudinal fluctuation in mammographic percent density differentiates between interval and screen-detected breast cancer. *International Journal of Cancer*. 2017;140(1):34-40.
55. Ugalde-Morales E, Li J, Humphreys K, Ludvigsson JF, Yang H, Hall P and **Czene K**. Common shared genetic variation behind decreased risk of breast cancer in celiac disease. *Scientific Reports*. 2017;7(1):5942.
56. Yang H, Brand JS, Fang F, Chiesa F, Johansson AL, Hall P and **Czene K**. Time-dependent risk of depression, anxiety, and stress-related disorders in patients with invasive and in situ breast cancer. *International Journal of Cancer*. 2017;140(4):841-52.

57. Yang H, Brand JS, Li J, Ludvigsson JF, Ugalde-Morales E, Chiesa F, Hall P and **Czene K**. Risk and predictors of psoriasis in patients with breast cancer: a Swedish population-based cohort study. *BMC Medicine*. 2017;15(1):154.
58. (more than 50 authors) Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, ..., **Czene K**, ..., and Simard J. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*. 2017;49(12):1767-78.
59. (more than 50 authors) Michailidou K, Lindstrom S, Dennis J, Beesley J, Hui S, ..., **Czene K**, ...and Easton DF. Association analysis identifies 65 new breast cancer risk loci. *Nature*. 2017;551(7678):92-4.
60. Tobin NP, Lundberg A, Lindstrom LS, Harrell JC, Foukakis T, Carlsson L, Einbeigi Z, Linderholm BK, Loman N, Malmberg M, Ferno M, **Czene K**, Perou CM, Bergh J, Hatschek T, Group TEXT. PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. *Clinical Cancer Research*. 2017;23(23):7225-31.
61. Hjelmborg J, Korhonen T, Holst K, Skytthe A, Pukkala E, Kutschke J, Harris JR, Mucci LA, Christensen K, **Czene K**, Adami HO, Scheike T, Kaprio J, Nordic Twin Study of Cancer c. Lung cancer, genetic predisposition and smoking: the Nordic Twin Study of Cancer. *Thorax*. 2017;72(11):1021-7.
62. Lundberg A, Lindstrom LS, Harrell JC, Falato C, Carlson JW, Wright PK, Foukakis T, Perou CM, **Czene K**, Bergh J, Tobin NP. Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts. *Clinical Cancer Research*. 2017;23(24):7512-20.
63. Eriksson M, **Czene K**, Pawitan Y, Leifland K, Darabi H, Hall P. A clinical model for identifying the short-term risk of breast cancer. *Breast Cancer Research*. 2017;19(1):29.

2016

64. Brand JS, Hedayati E, Humphreys K, Ludvigsson JF, Johansson AL, Bergh J, Hall P and **Czene K**. Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients. *Clinical Cancer Research*. 2016;22(21):5249-55.
65. Brand JS, Colzani E, Johansson AL, Giesecke J, Clements M, Bergh J, Hall P and **Czene K**. Infection-related hospitalizations in breast cancer patients: Risk and impact on prognosis. *Journal of Infection*. 2016;72(6):650-8.
66. Colzani E, Clements M, Johansson AL, Liljegren A, He W, Brand J, Adolfsson J, Fornander T, Hall P and **Czene K**. Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study. *British Journal of Cancer*. 2016;115(11):1400-7.
67. Holm J, Li J, Darabi H, Eklund M, Eriksson M, Humphreys K, Hall P and **Czene K**. Associations of Breast Cancer Risk Prediction Tools With Tumor Characteristics and Metastasis. *Journal of Clinical Oncology*. 2016;34(3):251-8.
68. Li J, Humphreys K, Eriksson M, Dar H, Brandberg Y, Hall P and **Czene K**. Worse quality of life in young and recently diagnosed breast cancer survivors compared with female survivors of other cancers: A cross-sectional study. *International Journal of Cancer*. 2016;139(11):2415-25.
69. Li J, Holm J, Bergh J, Eriksson M, Darabi H, Lindstrom LS, Tornberg S, Hall P, **Czene K**. Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers. *Annals of Oncology*. 2016;27(6):1181.
70. Strand F, Humphreys K, Cheddad A, Tornberg S, Azavedo E, Shepherd J, Hall P and **Czene K**. Novel mammographic image features differentiate between interval and screen-detected breast cancer: a case-case study. *Breast Cancer Research*. 2016;18(1):100.

71. Sackey H, Hui M, **Czene K**, Verkooijen H, Edgren G, Frisell J, Hartman M. The impact of in situ breast cancer and family history on risk of subsequent breast cancer events and mortality - a population-based study from Sweden. *Breast Cancer Research*. 2016;18(1):105.
72. (more than 50 authors) Kar SP, Beesley J, Amin Al Olama A, Michailidou K, Tyrer J, ..., **Czene K**, ..., and Lambrechts D. Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. *Cancer Discovery*. 2016;6(9):1052-67.
73. (more than 50 authors) Schmidt MK, Hogervorst F, van Hien R, Cornelissen S, Broeks A, ..., **Czene K**, ..., and Easton DF. Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. *Journal of Clinical Oncology*. 2016;34(23):2750-60.
74. Lu D, Andersson TM, Fall K, Hultman CM, **Czene K**, Valdimarsdottir U, Fang F. Clinical Diagnosis of Mental Disorders Immediately Before and After Cancer Diagnosis: A Nationwide Matched Cohort Study in Sweden. *JAMA Oncology*. 2016;2(9):1188-96.
75. Mucci LA, Hjelmborg JB, Harris JR, **Czene K**, Havelick DJ, Scheike T, Graff RE, Holst K, Moller S, Unger RH, McIntosh C, Nuttall E, Brandt I, Penney KL, Hartman M, Kraft P, Parmigiani G, Christensen K, Koskenvuo M, Holm NV, Heikkila K, Pukkala E, Skytthe A, Adami HO, Kaprio J, Nordic Twin Study of Cancer C. Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. *JAMA*. 2016;315(1):68-76.
76. (more than 50 authors) Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, ..., **Czene K**, ..., and Goldgar DE. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. *Journal of National Cancer Institute*. 2016;108(2).

2015

77. Brand JS, Li J, Humphreys K, Karlsson R, Eriksson M, Ivansson E, Hall P and **Czene K**. Identification of two novel Mammographic Density loci at 6Q25.1. *Breast Cancer Research*. 2015;17(1):75.
78. He W, Fang F, Varnum C, Eriksson M, Hall P and **Czene K**. Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer. *Journal of Clinical Oncology*. 2015;33:2262-9.
79. Holm J, Humphreys K, Li J, Ploner A, Cheddad A, Eriksson M, Tornberg S, Hall P and **Czene K**. Risk Factors and Tumor Characteristics of Interval Cancers by Mammographic Density. *Journal of Clinical Oncology*. 2015;33(9):1030-7.
80. Li J, Holm J, Bergh J, Eriksson M, Darabi H, Lindstrom LS, Tornberg S, Hall P, **Czene K**. Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers. *Annals of Oncology*. 2015;26(3):517-22.
81. Klevebring D, Lindberg J, Rockberg J, Hilliges C, Hall P, Sandberg M and **Czene K**. Exome sequencing of contralateral breast cancer identifies metastatic disease. *Breast Cancer Research and Treatment*. 2015;151(2):319-24.
82. Pawitan Y, Yin L, Setiawan A, Auer G, Smedby KE and **Czene K**. Distinct effects of anti-inflammatory and anti-thrombotic drugs on cancer characteristics at diagnosis. *European Journal of Cancer*. 2015;51(6):751-7.
83. Chen R, Regodon Wallin A, Sjolander A, Valdimarsdottir U, Ye W, Tiemeier H, Fall K, Almqvist C, **Czene K**, Fang F. Childhood injury after a parental cancer diagnosis. *Elife*. 2015;4.
84. (more than 50 authors) Day FR, Ruth KS, Thompson DJ, Lunetta KL, Pervjakova N, ..., **Czene K**, ..., and Murray A. Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. *Nature Genetics*. 2015;47(11):1294-303.

85. Abrahamsson L, **Czene K**, Hall P, Humphreys K. Breast cancer tumour growth modelling for studying the association of body size with tumour growth rate and symptomatic detection using case-control data. *Breast Cancer Research*. 2015;17:116.
86. (more than 50 authors) Guo Q, Schmidt MK, Kraft P, Canisius S, Chen C, ..., **Czene K**, ..., and Pharoah PD. Identification of novel genetic markers of breast cancer survival. *Journal of National Cancer Institute*. 2015;107(5).
87. (more than 50 authors) Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, ..., **Czene K**, ..., and Easton DF. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. *Nature Genetics*. 2015;47(4):373-80.

2014

88. Brand JS, Humphreys K, Thompson DJ, Li J, Eriksson M, Hall P and **Czene K**. Volumetric mammographic density: heritability and association with breast cancer susceptibility loci. *Journal of the National Cancer Institute*. 2014;106(12).
89. Colzani E, Johansson AL, Liljegren V, Foukakis T, Clements M, Adolfsson J, Hall P and **Czene K**. Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, patient and tumor characteristics. *British Journal of Cancer*. 2014;110(5):1378-84.
90. Lindstrom LS, Li J, Lee M, Einbeigi Z, Hartman M, Hall P and **Czene K**. Prognostic information of a previously diagnosed sister is an independent prognosticator for a newly diagnosed sister with breast cancer. *Annals of Oncology*. 2014;25(10):1966-72.
91. Pettersson A, Graff RE, Ursin G, Santos Silva ID, McCormack V, Baglietto L, Vachon C, Bakker MF, Giles GG, Chia KS, **Czene K**, Eriksson L, Hall P, Hartman M, Warren RM, Hislop G, Chiarelli AM, Hopper JL, Krishnan K, Li J, Li Q, Pagano I, Rosner BA, Wong CS, Scott C, Stone J, Maskarinec G, Boyd NF, van Gils CH, Tamimi RM. Mammographic density phenotypes and risk of breast cancer: a meta-analysis. *Journal of National Cancer Institute*. 2014;106(5).

2013

92. Sandberg MEC, Li J, Hall P, Hartman M, dos-Santos-Silva I, Humphreys K and **Czene K**. Change of mammographic density predicts the risk of contralateral breast cancer -a case-control study. *Breast Cancer Research*, 2013;15(4):R57.
93. Sandberg MEC, Alkner S, Hartman M, Eloranta S, Ryden L, Ploner A, Adami HO, Hall P and **Czene K**. Influence of Radiotherapy for the First Tumor on Aggressiveness of Contralateral Breast Cancer. *International Journal of Cancer*. 2013;132(10):2388-94.
94. Jonsson F, Yin L, Lundholm C, Smedby KE, **Czene K**, Pawitan Y. Low-dose aspirin use and cancer characteristics: a population-based cohort study. *British Journal of Cancer*. 2013;109(7):1921-5.
95. Li J, Humphreys K, Eriksson L, Edgren G, **Czene K**, Hall P. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer. *Journal of Clinical Oncology*. 2013;31(18):2249-56.
96. (more than 50 authors) Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, ..., **Czene K**, ..., and Kraft P. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. *Nature Genetics*. 2013;45(4):392-8, 8e1-2.

2012

97. Sandberg MEC, Hall P, Hartman M, Johansson AL, Eloranta S, Ploner A and **Czene K**. Estrogen Receptor Status in Relation to Risk of Contralateral Breast Cancer-a Population-Based Cohort Study. *PLoS One*. 2012;7(10):e46535.
98. Sandberg MEC, Hartman M, Klevebring D, Eloranta S, Ploner A, Hall P and **Czene K**. Prognostic Implications of Estrogen Receptor Pattern of Both Tumors in Contralateral Breast Cancer. *Breast Cancer Research and Treatment*. 2012;134(2):793-800.
99. (more than 50 authors) Ghoussaini M, Fletcher O, Michailidou K, Turnbull C, Schmidt MK, ..., **Czene K**, ..., and Easton DF. Genome-wide association analysis identifies three new breast cancer susceptibility loci. *Nature Genetics*. 2012;44(3):312-8.
100. Rebora P, Lee M, **Czene K**, Valsecchi MG, Reilly M. High risks of familial chronic lymphatic leukemia for specific relatives: signposts for genetic discovery? *Leukemia*. 2012;26(11):2419-21.
101. Varghese JS, Thompson DJ, Michailidou K, Lindstrom S, Turnbull C, Brown J, Leyland J, Warren RM, Luben RN, Loos RJ, Wareham NJ, Rommens J, Paterson AD, Martin LJ, Vachon CM, Scott CG, Atkinson EJ, Couch FJ, Apicella C, Southey MC, Stone J, Li J, Eriksson L, **Czene K**, Boyd NF, Hall P, Hopper JL, Tamimi RM, Consortium M, Rahman N, Easton DF. Mammographic breast density and breast cancer: evidence of a shared genetic basis. *Cancer Research*. 2012;72(6):1478-84.

2011

102. Colzani E, Liljegren A, Johansson AL, Adolfsson J, Hellborg H, Hall PF and **Czene K**. Prognosis of Patients with Breast Cancer: Causes of Death and Effects of Time since Diagnosis, Age, and Tumor Characteristics. *Journal of Clinical Oncology*. 2011;29(30):4014-21.
103. Lindstrom S, Vachon CM, Li J, Varghese J, Thompson D, Warren R, Brown J, Leyland J, Audley T, Wareham NJ, Loos RJ, Paterson AD, Rommens J, Waggott D, Martin LJ, Scott CG, Pankratz VS, Hankinson SE, Hazra A, Hunter DJ, Hopper JL, Southey MC, Chanock SJ, Silva Idos S, Liu J, Eriksson L, Couch FJ, Stone J, Apicella C, **Czene K**, Kraft P, Hall P, Easton DF, Boyd NF, Tamimi RM. Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. *Nature Genetics*. 2011;43(3):185-7.
104. (more than 50 authors) Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, ..., **Czene K**, ..., and Garcia-Closas M. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. *Journal of National Cancer Institute*. 2011;103(3):250-63.
105. Miao H, Verkooijen HM, Chia KS, Bouchardy C, Pukkala E, Larønningen S, Mellekjaer L, **Czene K**, Hartman M. Incidence and outcome of male breast cancer: an international population-based study. *Journal of Clinical Oncology*. 2011;29(33):4381-6.